KhannaDFitzgeraldJKhannaP.2012American College of rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res2012;64(10):1431-46.
KimYShinSKimK.Effect of urate lowering therapy on renal disease progression in hyperuricemic patients with chronic kidney disease. J Rheumatol2015;42(11):2143-48.
4.
GoldfienRPressmanAJacobsonAet al. A pharmacist-staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Perm J2016;20(3):18-23.
5.
Nasser-GhodsiNHarroldLR.Overcoming adherence issues and other barriers to optimal care in gout. Curr Opin Rheumatol2015;27(2):134-8.
6.
KuoCGraingeMMallenCet al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis2015;74(4):661-7.
7.
KeenanRO’BrienWLeeKet al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med2011;124(2):155-63.
8.
StampLJordanS.The challenges of gout management in the elderly. Drugs Aging2011;28(8):591-608.
9.
RichettePDohertyMPascualEet al. 2016updated EULAR evidence-based recommendation for the management of gout. Ann Rheum Dis2017;76:29-42.
10.
Perez-RuizF.Treating to target: a strategy to cure gout. Rheumatology2009;48:ii9-ii14.
11.
KhannaDKhannaPFitzgeraldJ.2012American College of Rheumatology guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res2012;64(10):1447-61.
12.
QaseemAHarrisRForcieaMet al. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians. Ann Intern Med2017;166:58-68.
13.
TerkeltaubRFurstDBennettKet al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum2010;62(4): 1060-8.
14.
RostomAMoayeddiPHuntR; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther2009;29(5):481-96.
15.
KiltzUSmolenJBardinT.Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis2017;76:632-8.
16.
KrishnanESvendsenKNeatonJ; MRFIT Research Group. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med2008;168(10): 1104-10.
17.
UnderwoodM.Sugary drinks, fruit, and increased risk of gout. BMJ2008;336(7639):285-6.
18.
FravelMErnstM.Management of gout in the older adult. Am J Geriatr Pharmacother2011;9(5):271-85.
19.
KapurSKraagG. Gout and hyperuricemia: compendium of therapeutic choices. 2015. Available: https://www.e-therapeutics.ca/search (accessed Aug. 13, 2016).
GivertzMAnstromKRedfieldMet al. Effect of xanthine oxidase inhibition in hyperuricemic heart failure patients. Circulation2015;131(20):1763-71.
25.
National Kidney Foundation. A clinical update on gout: optimizing care for patients with chronic kidney disease. National Kidney Foundation, Inc. 2014. Available:https://www.kidney.org/content/gout-clinical-bulletin (accessed Jan. 15, 2017).